Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0095 | Pergolide

Molecular Formula C19H26N2S
Molecular Weight 314.5
Structure
State solid
Route of elimination The major route of excretion is the kidney.
Protein binding 0.9
Half life 27 hours
Absorption Significant amount may be absorbed (evidence on bioavailability still lacking).

N

N04BC02 Pergolide


[N04BC] Dopamine agonists


[N04B] DOPAMINERGIC AGENTS


[N04] ANTI-PARKINSON DRUGS


[N] Nervous system

Pictogram Signal Statements Precautionary Statement Codes
Danger

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.


H300 (100%): Fatal if swallowed [Danger Acute toxicity, oral]


H351 (100%): Suspected of causing cancer [Warning Carcinogenicity]


H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]


 P201, P202, P264, P270, P281, P301+P310, P308+P313, P321, P330, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

  • Dyskinesia

  • Parkinson's disease

  • Parkinsonism

  • Acute coronary syndrome (0.011)

  • Personality disorder (0.021)

  • Abdominal pain

  • Abnormal dreams

  • Akathisia

  • Akinesia

  • Anxiety

  • Arthralgia

  • Asthenia

  • Back pain

  • Chest pain

  • Chills

  • Confusional state

  • Constipation

  • Decreased appetite

  • Depression

  • Dermatitis

  • Diarrhoea

  • Diplopia

  • Dizziness

  • Dysgeusia

  • Dyskinesia

  • Dyspepsia

  • Dyspnoea

  • Extrapyramidal disorder

  • Eye disorder

  • Face oedema

  • Feeling abnormal

  • Gait disturbance

  • Gastrointestinal pain

  • Hallucination

  • Headache

  • Hiccups

  • Hyperhidrosis

  • Hypertension

  • Hypertonia

  • Infection

  • Influenza

  • Insomnia

  • Loss of consciousness

  • Muscle twitching

  • Musculoskeletal discomfort

  • Nausea

  • Neck pain

  • Oedema

  • Oedema peripheral

  • Orthostatic hypotension

  • Pain

  • Paraesthesia

  • Pollakiuria

  • Psychotic disorder

  • Rash

  • Rhinitis

  • Shock

  • Somnolence

  • Speech disorder

  • Syncope

  • Tremor

  • Urinary tract infection

  • Visual impairment

  • Weight increased

    • (2R,4R,7R)-4-[(methylsulfanyl)methyl]-6-propyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraene (6aR,9R,10aR)-9-(Methylthiomethyl)-7-propyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline (6aR,9R,10aR)-9-Methylsulfanylmethyl-7-propyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinolin-7-ium
    (6aR,9R,10aR)-9-Methylsulfanylmethyl-7-propyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinoline (8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline (8beta)-8-[(methylthio)methyl]-6-propylergoline
    104P221 24MJ822NZ9 5-Bromo-7-methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid (10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxo-octahydro-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-amide
    66104-22-1 9-Methylsulfanylmethyl-7-propyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinolin-7-ium(Pergolide) 9-Methylsulfanylmethyl-7-propyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinoline
    9-Methylsulfanylmethyl-7-propyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinoline 9-Methylsulfanylmethyl-7-propyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinoline(pergolide) 9-Methylsulfanylmethyl-7-propyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinoline, mesylate (Pergolide)
    AB00053740-13 AB00053740_14 AB00053740_15
    BCP18331 BDBM50017543 BDBM50028421
    BIDD:GT0177 BPBio1_000254 BPBio1_001211
    BRD-K60770992-001-01-8 BRD-K60770992-066-05-2 BRD-K60770992-066-15-1
    BSPBio_000230 BSPBio_003156 Biomol-NT_000025
    C-19410 C07425 CC-33590
    CCG-205064 CHEBI:63617 CHEMBL1275
    CHEMBL531 D-8beta-((Methylthio)methyl)-6-propylergoline D08339
    DB01186 DTXSID2023438 DivK1c_000442
    Ergoline, 8-((methylthio)methyl)-6-propyl-, (8beta)- GTPL48 HMS2089C18
    IDI1_000442 InChI=1/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s KBio1_000442
    KBio2_002127 KBio2_004695 KBio2_007263
    KBio3_002656 KBioGR_001409 KBioSS_002127
    LS-64479 LY 141B LY-127,809
    LY-127809 Lopac0_000984 NCGC00017366-02
    NCGC00017366-03 NCGC00017366-04 NCGC00017366-05
    NCGC00017366-06 NCGC00017366-10 NCGC00142538-01
    NCGC00142538-02 NCGC00142538-03 NINDS_000442
    P2200 Pergolida Pergolida [INN-Spanish]
    Pergolide (INN) Pergolide [INN:BAN] Pergolidum
    Pergolidum [INN-Latin] Permax Permax (TN)
    Prestwick0_000295 Prestwick1_000295 Prestwick2_000295
    Prestwick3_000295 Q415752 SBI-0050957.P003
    SCHEMBL26921 SPBio_002099 SPBio_002449
    SR-01000721840 SR-01000721840-8 ST057534
    Spectrum2_001970 Spectrum3_001588 Spectrum4_000835
    Spectrum5_001649 Spectrum_001647 TNP00315
    UNII-24MJ822NZ9 YEHCICAEULNIGD-MZMPZRCHSA-N ZINC3786466
    [2-(1H-Indol-4-yl)-ethyl]-methyl-amine cid_47811 compound with methanesulfonic acid
    pergolide

    DrugBank Name Pergolide
    DrugBank DB01186
    CAS Number 66104-22-1, 66104-23-2
    PubChem Compound 47811
    KEGG Compound ID C07425
    KEGG Drug D08339
    PubChem.Substance 46507604
    ChEBI 63617
    PharmGKB PA450873
    ChemSpider 43503
    BindingDB 50017543.0
    TTD DAP000069
    Wikipedia Pergolide
    DPD 11339

    1. Dykens et al. (2007)